Degarelix in prostate cancer 22. Doehn C, Sommerauer M, Jocham D. Drug evaluation: Degarelix – a potential new therapy for prostate cancer. IDrugs. 2006;9(8):565–572. 23. US Food and Drug Administration. Degarelix. Dec 29, 2008. Accessed on Feb 14, 2009. Available from: http://www.fda.gov/cder/Ofﬁces/ OODP/whatsnew/Degarelix.htm. 24. Bubley GJ. Is the ﬂare phenomenon clinically signiﬁcant? Urology. 2001;58(2 Suppl 1):5–9. 25. US Food and Drug Administration. Plenaxis (abarelix for injectable suspension) Nov 25, 2003. Accessed on Feb 14, 2009. Available from: http://www.fda.gov/cder/drug/infopage/plenaxis/default.htm. 26. Speciality European Pharma. 2009. Accessed on Feb 14, 2009. Avail- able from: http://www.specialityeuropeanpharma.com. 27. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173–181. 28. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–4456. 29. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19(17):3750–3757. 30. Shariﬁ N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–244. 31. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimiz- ing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int. 2006;98(1):20–27. 32. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; And the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–1500. Clinical Interventions in Aging 2009:4 223